ADC Therapeutics (ADCT) Receivables (2021 - 2023)
Historic Receivables for ADC Therapeutics (ADCT) over the last 3 years, with Q3 2023 value amounting to $21.2 million.
- ADC Therapeutics' Receivables fell 890.71% to $21.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $21.2 million, marking a year-over-year decrease of 890.71%. This contributed to the annual value of $73.8 million for FY2022, which is 13793.34% up from last year.
- According to the latest figures from Q3 2023, ADC Therapeutics' Receivables is $21.2 million, which was down 890.71% from $23.9 million recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Receivables registered a high of $73.8 million during Q4 2022, and its lowest value of $2079.0 during Q2 2021.
- Its 3-year average for Receivables is $21.8 million, with a median of $22.2 million in 2022.
- Its Receivables has fluctuated over the past 5 years, first surged by 100341130.35% in 2022, then crashed by 890.71% in 2023.
- Quarter analysis of 3 years shows ADC Therapeutics' Receivables stood at $31.0 million in 2021, then surged by 137.93% to $73.8 million in 2022, then tumbled by 71.29% to $21.2 million in 2023.
- Its last three reported values are $21.2 million in Q3 2023, $23.9 million for Q2 2023, and $24.0 million during Q1 2023.